InterValue Partners

InterValue Partners is a venture capital investment firm based in Seoul, South Korea, founded in 2016. It provides venture capital and corporate venture capital services and focuses on technology companies, with investments across South Korea.

Min Kyung-wan

Team leader

20 past transactions

Unastella

Series A in 2024
Unastella develops and operates its own space launch vehicles to provide human space travel platform services, delivering civilian, manned launch capabilities to enable quasi-orbital space travel for passengers.

Fescaro

Series B in 2024
Fescaro Co., Ltd. is a specialized company based in Seongnam, South Korea, that focuses on developing cybersecurity software solutions specifically for the automotive industry. Founded in 2016, the company provides comprehensive security systems that address vulnerabilities at various levels, including vehicle electronic control units (ECUs), in-vehicle networks, and vehicle-to-everything (V2X) communication. Fescaro's product offerings include FAST HSM, which ensures the integrity of ECU firmware and creates a secure environment for both firmware and drivers; FAST IDS, designed to detect a range of cybersecurity threats; and FAST VTI, which offers security audits and updates. The company aims to enhance the cybersecurity framework for self-driving and connected vehicles, leveraging advanced technologies to address the limitations of existing security measures. Fescaro Co., Ltd. reflects a commitment to innovation in automotive cybersecurity, driven by a team of experienced developers and ethical hackers.

Caredoc

Series B in 2023
Caredoc is a platform dedicated to elderly care, designed to facilitate the connection between consumers seeking reliable care services and providers offering these services. The platform addresses the challenge of information accessibility, as families often struggle to find accurate details about elderly care facilities online or through informal channels. By providing verified information about care service providers, Caredoc enhances transparency and trust in the selection process. Additionally, it features quick matching functions and detailed caretaker profiles, allowing families to easily search for various clinics, hospitals, and doctors based on their specific needs, complete with reviews and ratings. This comprehensive approach helps streamline the search for quality elderly care, benefiting both families and care providers.

Unastella

Seed Round in 2023
Unastella develops and operates its own space launch vehicles to provide human space travel platform services, delivering civilian, manned launch capabilities to enable quasi-orbital space travel for passengers.

Absology

Series B in 2022
Developer of in-vitro diagnostic systems aiming to save lives. The company offers a range of diagnostic kits for conditions like testosterone deficiency, vitamin D insufficiency, prostate cancer (PSA), thyroid disorders (TSH, FreeT4), and pituitary tumors (PCT). Additionally, Absology's platform aids in monitoring anti-cancer therapies, cardiovascular diseases, and Alzheimer's disease.

bHaptics

Series B in 2022
bHaptics specializes in full-body haptic technology, offering a high-end vest with 40 feedback points that provides lag-free wireless touch sensations. Compatible with various platforms and games, it enhances virtual reality experiences.

AI Korea

Venture Round in 2022
AI Korea is a manufacturer specializing in precision parts for battery production. Its product portfolio includes an electrolyte supply device system, secondary batteries, dust collectors, and cleaning equipment, supported by research and development facilities and measuring instruments.

PMX

Series A in 2021
PMX is a medical technology company that delivers personalized health insights using a breakthrough AI-assisted imaging platform. Founded in April 2021, PMX has developed an automated multi-modality imaging platform, called MediOMX, to build end-to-end applications that measure the vital organs and tissues of the body for universal care and wellness. PMX product pipeline is designed such that it does not distract the existing radiological workflow, instead, it improves the current one by connecting the chain of image acquisition, processing, and reporting system. Our quick, accurate, and cost-effective solutions are highly beneficial to all stakeholders in the imaging ecosystem including patients, referring clinicians, radiologists, and administration. Using this end-to-end platform, we have built 3 main use cases as follows: - 15 minutes dementia screening using brain MRI; - Full body MRI screening for assessing an athlete's body and performing injury risk analysis; - Chest CT screening for various lung diseases particularly infiltrating pneumonia such as COVID-19

Vueron

Series A in 2021
Vueron specializes in LiDAR solutions for automotive and industrial applications. They develop AI-based algorithms to enable high-performance object detection around sensors, using minimal computing resources. The company partners with OEMs and industry players to create practical LiDAR solutions tailored to clients' needs.

DEEPX

Series B in 2021
DEEPX is a Korean software and hardware company specializing in artificial intelligence solutions. It develops next-generation neural networks that enhance AI silicon for deep learning applications. By focusing on the core properties of neural networks, DEEPX maximizes memory bandwidth, enabling edge devices to efficiently run advanced AI models. This technology allows companies to implement power-efficient on-device AI, promoting sustainable operations in various applications.

Cenyx Biotech

Series A in 2021
Cenyx Biotech develops diagnostic and therapeutic nano compounds based on nanozymes and nanoparticles. It is advancing a nano-biotech platform to transform healthcare by engineering agents that simultaneously scavenge reactive oxygen species, including superoxide, hydrogen peroxide, and hydroxyl radicals. This approach aims to reduce excessive inflammatory responses in the early stage of subarachnoid hemorrhage, potentially improving patient outcomes.

Heart It

Seed Round in 2020
Heart It Co., Ltd., based in Seoul, South Korea, operates an online fashion marketplace. It curates and offers a range of clothing, accessories, and lifestyle products, enabling users to stay updated with the latest trends and meet their fashion needs. The company, a subsidiary of SNOW Corp., also provides information about wardrobes of K-street style stars.

DEEP INSPECTION

Series A in 2020
DEEP INSPECTION offers customized software development services.

Inner bottle

Seed Round in 2020
Innerbottle is a company that specializes in creating eco-friendly and innovative packaging solutions through its formulated polymer inner containers. These inner containers are designed to fit within any external container, ensuring safe and proper use while enhancing user satisfaction. The unique elastic material used in their products promotes a zero-waste approach, contributing to a sustainable environment. By focusing on environmentally responsible packaging, Innerbottle aims to provide consumers with effective and safe options that align with modern sustainability goals.

Laserssel

Series C in 2020
Laserssel Co Ltd specializes in the manufacturing and distribution of advanced optical technologies, including beam-shaping optics, optical lasers, laser selective reflow systems, and laser compression bonders. The company serves a diverse range of sectors, such as semiconductor manufacturing, high-end displays, automotive applications, consumer electronics, military technologies, and industrial processes. By providing innovative solutions in laser technology, Laserssel supports the growing demands of these industries with its cutting-edge products.

NanudaKitchen

Series A in 2019
NanudaKitchen is a shared store & share kitchen platform that provides sales settlement, kiosk app solution and marketing services.

MDimune

Series B in 2019
MDimune Inc. is a South Korean therapeutics company focused on developing innovative drug delivery systems. Founded in 2015 and based in Seoul, the company specializes in the creation of cancer therapeutics using immune cell-derived and stem cell-derived vesicles. Its research and development efforts encompass a range of therapeutic areas, including personalized cancer treatments, osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative disorders. MDimune's proprietary platform enables targeted delivery of drugs, allowing for the development of novel therapeutics that enhance treatment efficacy. The company provides its vesicle-based delivery solutions to biotech and pharmaceutical enterprises, thereby facilitating advanced therapeutic options for patients.

Laserssel

Series B in 2018
Laserssel Co Ltd specializes in the manufacturing and distribution of advanced optical technologies, including beam-shaping optics, optical lasers, laser selective reflow systems, and laser compression bonders. The company serves a diverse range of sectors, such as semiconductor manufacturing, high-end displays, automotive applications, consumer electronics, military technologies, and industrial processes. By providing innovative solutions in laser technology, Laserssel supports the growing demands of these industries with its cutting-edge products.

Laserssel

Series A in 2017
Laserssel Co Ltd specializes in the manufacturing and distribution of advanced optical technologies, including beam-shaping optics, optical lasers, laser selective reflow systems, and laser compression bonders. The company serves a diverse range of sectors, such as semiconductor manufacturing, high-end displays, automotive applications, consumer electronics, military technologies, and industrial processes. By providing innovative solutions in laser technology, Laserssel supports the growing demands of these industries with its cutting-edge products.

PharmAbcine

Venture Round in 2017
PharmAbcine, Inc. is a biotechnology company based in Daejeon, South Korea, focused on developing fully human therapeutic monoclonal antibodies (mAb) for the treatment of cancer and inflammatory diseases. The company primarily engages in the out-licensing of candidate therapeutics and clinical applications, aiming to create first-in-class and best-in-class mAb. Its key projects include TTAC0001, an anti-angiogenic mAb targeting VEGFR-2, as well as innovative dual-specific antibody technologies such as DIG-body and PIG-body. PharmAbcine has established a strategic partnership with Samsung Biologics for the development and manufacturing of its PMC-403 pipeline, a therapeutic candidate aimed at addressing neovascular disorders. The company leverages a strong management team with expertise in therapeutic antibody discovery and development, supported by renowned scientific advisors in the field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.